Open Access<p>First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against <em>Pseudomonas aeruginosa</em> Isolated from Patients with Urinary Tract Infection in Tehran, Iran</p>
Author(s) -
Mohammad Rahimzadeh,
Mehri Habibi,
Saeid Bouzari,
Mohammad Reza Asadi Karam
Publication year - 2020
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s243301
Subject(s) - ceftazidime/avibactam , pseudomonas aeruginosa , medicine , antimicrobial , ceftazidime , microbiology and biotechnology , urinary system , pharmacology , biology , bacteria , genetics
Pseudomonas aeruginosa causes complicated and/or nosocomial UTI. These infections are usually associated with severe and multi-drug resistant P. aeruginosa isolates. As there is no study about the activity of novel antibiotics ceftazidime-avibactam (CZA) and ceftolozane-tazobactam (C/T) against P. aeruginosa isolates in Iran, we aimed to evaluate for the first time the efficacy of these agents against P. aeruginosa isolated from patients with UTI in Iran. Then, the genetic diversity of the resistant isolates was assayed.